Moving with the times: a new generation joint health solution for today’s consumer
28 Mar 2019 | Lonza
The NutritionInsight webinar “Moving with the times: a new generation joint health solution for today’s consumer” offers insights into the changing consumer landscape, including the expectations of both aging and active consumers and rising demand for joint health solutions. Dominik Mattern of Lonza Capsugel discusses the science behind Lonza’s UC-II undenatured type II collagen ingredient, including its unique mode of action and how it can meet the needs of a new and growing consumer base. He presents a first look at Lonza’s new generation of ready-to-market innovative dosage forms and formulations that address mobility concerns related to healthy aging.
Brought to you by
A warm welcome to all of today's webinars viewers from all across the globe.
My name is Robin Wires, and I'm the chief editor of CNS Media, which is the publisher of The World of Food Ingredients, Food Ingredientsfirst.com and nutrition nutritionInsight.com.
And today's Nutrition Insight webinar is entitled Moving with the Times, A New Generation Joint Health Solution for today's Consumer, and it's sponsored by Lanza Capsu Gel.
And I think it's very timely to, to really show how joint health is taking off in product development right now.
And today's webinar is really going to offer insights into the changing consumer landscape, including the expectations of both aging and active consumers and the rising demand for joint health solutions.
So Dominic Mattern will discuss the science behind Lonzo's UC to, unddenatured type to collagen ingredients, which will include its unique mode of action and how it can meet the needs of a new and growing consumer base.
And he's going to also present a first look at Lonzo's new generation of ready to market innovative dosage forms and formulations, and these really address mobility concerns that relate to healthy aging.
So it's certainly, certainly something to look forward to.
But before we get to that, I'm going to give a bit of a background to the market and based on some of the recent Enova Market insights work into this area.
So products featuring bone and joint health claims are really on the rise, and if we look at an index number of new products tracked with a bone or joint health claim globally and we take 2014 as a base, we found a compound annual growth rate of 13% from 2014 to 2018.
And there were 66% more products tracked in 2018 with these types of claims.
And if you take a couple of examples of the types of products that are trending, we see products like New Life Therapeutic bone therapy, which is available in Canada with the claim, build strong bones, help to prevent osteoporosis and bone loss, and the product contains supportive ingredients like magnesium, vitamin D, vitamin K2 to help build better bones and prevent osteopathy and bone loss.
And in Hong Kong, in overmarket insight has tracked life nutrition, joint support, fast relief dietary supplement.
And this product contains a whole host of joint health ingredients such as glucosamine, chondroitin, MSM, and collagen.
And the product features the following claims, quote, replenish and lock joint lubrication fluid, strengthen cartilage and prevent wear, repair and rebuild the abrasive part, and improve joint flexibility.
So bone and joint applications across the food and beverage categories are really trending.
So supplements still dominate for 2018 launches, 2018 launches featuring bone and joint health claims, but the percentage that this accounts for has really dipped from 45% in 2014 to 36% in 2018, so a 9% drop.
And these claims on baby and toddler foods have tapered off as a share as , with the highest rises really happening in dairy, and the dairy sector rose from 12% in 2014 to 18% in 2018, so a very significant rise.
And the most interesting rise is really in the sports nutrition field which went from just 4% of launches in 2014 to 12% in 2018, so trebling.
And bone and joint health claims on infant nutrition and foods for expectant mothers typically opt for vitamin D or calcium fortification.
So for example, from the UK we see nutritia and nutrientum pregnancy bars, and this raisin and chocolate variety features a vitamin D which contributes to the maintenance of normal bones.
And Novolac vanilla flavored growing up milk formula for juniors from Portugal features the claim, quote, calcium and vitamin D are needed for normal growth and the development of babies' bones.
So it's very important to place activity in the bone and joint health space in context, of course, as it's still a very, very small percentage of NPD in the food and beverage industry as a whole.
So the percentage ranges from less than 1% point in Latin America to almost 3% in Australasia, where 19% tigger has been reported from 2014 to 2018 when we assess new product activity.
The Kagger activity in Europe is even slightly higher at 20%.
But in the, in, in the region, the number of products with the bone and joint health claim has enjoyed Kagger of 20% from 0.9% in 2014 to 1.5% in 2018.
So it's quite a significant launch in increase in launches.
And in 2018, 1.9% of all new food and beverages and supplement launches tracked in Asia featured a bone or joint health claim, with the region perhaps being the most stable for products with this type of positioning.
And I guess it could also be down to the bit more tradition existing in that region for these type of claims.
But having said that, North America's even dipped somewhat, when it comes, if you look at this period as a whole.
So if we look more closely at the growth areas for bone and joint health products in EMEA, we see that sports nutrition really tops the fastest growing market categories of new products with a bone and or a joint health claim when it comes to Kagger from 2014 to 2018.
And, sports nutrition enjoyed a tag of 89% over this period ahead of supplements and dairy on 19% growth.
Now, particularly interesting to note in the region is the growth in products containing collagen type 2, and of the new product launches with the bone and or joint health claims, 57% growth has been reported from 2014 to 2018.
Again, it's important to note that we have a very, very small base, it's just 0.3% in 2014 to 0.8% in 2018, but if you extrapolate that further, it's quite significant, I guess.
Now examples include joint health dietary supplement from Switzerland, which is enriched with highly effective undenatured type 2 UC2 collagen.
Now bone and joint health products are increasingly highlighting healthy aging, and as a percentage of all launches featuring bone and joint health claims globally in 2018, 44% featured healthy aging claims, which was up from 35% in 2014, and this relates equates to a tagger of 20% over this period.
Now an example of this is Purity products Meress Plus probiotics dietary supplement, which is a vegetarian capsule, and the product is claimed to support joint comfort and digestive health with a formulation that contains magnesium and resveratrol, and it has the ability to support and maintain.
Healthy joints, bones, muscle, heart function, and healthy aging, brain health and energy levels.
I think it's quite interesting to see these types of ingredients being used.
I think particularly resveratrol appears in an awful lot of healthy aging products, and this is really something that's quite on trend.
So this new product dynamic is really happening amid an increasing amid increasing expectations from the 55+ customer group who are really looking to stay mobile and healthy.
And in over aging supplements lifestyle survey that was conducted in 2017 found that 21% of UK consumers over the age of 50 have used prescription medication for joint health in 2017, while 7% of UK consumers.
Over 55 have used prescription medication for bone health in 2017.
So these are quite significant numbers, and Western markets are less likely to feature products specifically targeted at older adults and seniors, however, but in Asian markets, there's more of a tradition for this.
So for example, you see the product there on the right, the Aleen Gold chocolate milk powder from Singapore.
It features a new unique formula which is specifically marketed as being developed for adults aged 51 years and over.
Now, the ingredient list features collagen and is also high in calcium and protein.
So a very big opportunity there.
So this, this market dynamic is really happening as collagen ingredients increasingly step into the spotlight.
And if we look at the index number of new product launches tracked with collagen ingredients globally and we take 2014 as a base of 100, we find that it truly peaked 2018 with almost twice as many products tracked.
Last year, as they were in 2014.
Now Kagger of 17% has been reported over this period.
And healthy aging and anti-aging are key on this platform.
So for example, we've reported Paleo Ranch strawberry peak and Skinny Bar from From the US, which contains the collagen to quote which promotes anti-aging and healthy joints, skin, tendons, connective tissue, and cartilage.
We've also seen Vitaglow original natural marine collagen supplement from the very interesting Australian market, and this features the claim Vitaglo uses type 1 collagen which is specific for hair, skin, and nail benefits.
And skin benefits increases skin by up to 91%, and anti-aging improves skin elasticity and firmness, and it improves sun damaged skin.
So quite a lot of claims being made on that type of product for for something using, using collagen in its formulation.
Just to reiterate, if we look at the fastest growing market categories of new products tracked with collagen ingredients globally, and we looked at the Kagger from 2014 to 2018, you could find that certain sports sectors are really trending, and these include sports bars at 61% growth, sports powders at 41% growth.
But meat snacks have also gained an increasing reputation in the sports arena on a high protein platform, and collagen is only helping within this as.
So gummies and jellies, which I guess is where gelatin has traditionally been used, are also really unsurprising applications for collagen ingredients.
And here are a couple of further NPD launches on this platform.
So we have not so bold Bites Power, fuel plus collagen, 7 nuts and seed butter snack bar.
And we have sports research collagen peptides, dietary supplement with vanilla bean flavor, so you can see really innovation coming across the across the board whether it could be in the sports bars, powders, really, really anything, and it goes far beyond the traditional kind of applications.
So finally, we see again that collagen is finding diverse applications across market categories and they could include sports, nutrition, dairy, and spreads.
So for example, we see this product called Rich Piana 5% nutrition Joint Defender maximum.
And this is a dietary supplement product for joint support from the US and it features the claim quote collagen is the main component of connective tissue.
And it notes type type 2 collagen is a peptide and component of joint cartilage, meaning that it plays a vital role in the recovery process.
But again, it's interesting claims are being made across the board and it's just interesting to see how some of these things are being adopted, and you see here products from all over the place doing this.
So that was my little partner on the market and so thanks for your attention for that.
What we're going to do now is our second speaker I'm going to introduce is Dominic Matur who is the head of business development EMEA for consumer health and nutrition at Lanza, which is a global leader in the pharmaceutical, biotechnology and healthcare industries.
Now Dominic holds a degree in food chemistry and started his career at Swiss Caps in 2001 where he was responsible for the research and development for dietary supplements and OTC products.
And in 2005, he changed to sales management at Capsgel, which is a manufacturer of innovative dosage forms.
And today Dominic manages business development in the EMEA and he identifies and evaluates new market segments and business areas, and he develops strategies to implement innovative products and concepts in cooperation with key accounts.
So Dominic, without further ado, the floor is yours.
Yeah, thank you very much for this nice introduction and a warm welcome also from my side to everyone joining today's webinar.
It's a pleasure to be here, a pleasure to be on the call and to speak a bit about a very exciting ingredient and active which is called UC2.
If I start with this slide here as, as maybe an opening towards.
UC 2 and bridging over from the nice introduction from Robin towards maybe the scientific aspects of UC2.
I wanted to start here and.
Just to make the link to Robin that indeed we have a very broad basket of consumers meanwhile that is looking after mobility of the joint health, and finally a form of independence which mobility ultimately is, and we see according to customer service or consumer research we did that 76% of boomers, so the older generation and about 70% of the Generation X, taking supplements.
In the biggest European countries, for example, Germany, Italy, and France, would like to use food supplements for joint health as , meaning that we have a very broad basket of consumers.
The main consumer targets might still be the senior people, boomers, and matures.
Looking to maintain joint mobility, but likewise we see great new opportunities in the sports supplements arena and in the proactive segment of customers where active millennials and Generation Xs are looking for recovery and performance maintenance.
Jumping to the next slide, what you see here is maybe an opening towards joint health in a way that we have displayed here a few nutritional strategies in joint health.
So on the left side, we speak about anti-inflammatory support, very, very trendy ingredients are listed here in this green bubble.
Like curcumin, the polyphenol from turmeric or bosweia, having a kind of a renaissance these days.
Proteolytic enzymes are used in joint care in the anti-inflammatory space like trypsin, papain, proomelane, semi, MSM, anti-inflammatory omega 3 fatty acids, and so on.
And the second big approach might be the supplementation of building blocks to nourish the joint.
Typical examples here are glucosamine chondrotine, but also the hyaluronic acid and what I would call a standard collagen.
And last but not least, it's also advised to look into an antioxidant and micronutrient supplementation, as, typically one suffers from elevated, oxidative stress, when the joint, the joint, and the knee joint, especially, is, facing, daily, stress and strain.
So these are three, researched or typical approaches towards joint care and I would like to introduce you to a missing bubble maybe and this is what is what is embedded in in the science of of UC2 and in the brand of UC UC2 which is then.
Coming from a different angle and which is a different mode of action, a different mechanism of action called oral tolerance.
UC2 is the brand standing for undine-natured type 2 collagen.
Undinatured is then nothing else than native, which is just a synonym ford.
Sounds quite chemically natured, but it's a native type 2 collagen, and this is very important for the for the mode of action and for.
How the product works, it is derived from chicken sternum cartilage, and Lanza has and owns a patent about this very special extraction process, how we get the UC2, the nad type of collagen, out of the chicken's sternum.
It is very important that this this molecule that you see on the right side, which is the collagen triple helix structure of the un-natured collagen type 2, that this molecular structure is maintained, and that's the magic about the manufacturing process to really make sure that this chemical information, this chemical configuration that is embedded in this molecule is maintained.
So actually it is manufactured in the USA under food GMP conditions and due to the chemical configuration as just explained, we derive to a very small dose of just 40 mg once per day.
Again, this is due to this unique mechanism of action called oral tolerance which has been clinically, pre-clinically and clinically substantiated.
I'll give you a bit more color on this slide, so what you see here are commercially available collagenin products.
And you see on this.
On this table on the left side, the UC2 brand, which is again this anti-natured collagen which is prepared without heat, no enzymes, a very gentle process so that this triple helical structure is retained.
There's also a structural representation of the molecule that you see here and in the last row you see that the UC2 brand still.
Is displaying intact polypeptides and active epitopes.
Epitopes are molecular regions that have certain, let's say, molecular information embedded and that is very important to maintain during the manufacturing process so that at a later stage an anti-chain antibody reaction can happen, which is very important for the anti-inflammatory mechanism and effect of UC2.
On the right side, so you see a few denatured products where we start from gelatin or collagen hydrolysates and then by more harsh methods like hydrolysis by heat or by enzymes or by acids or alkaline solutions you get to a disrupted molecular distribution.
That you see in these animations here where we're coming to a mixture of peptides and polypeptides or amino acids and small peptides that do not have any active epitopes anymore in the molecules, meaning that there is no anti-inflammatory information included yet, so these products can still be a kind of a building material for joint health, but the difference here really is As you see on the left, the very unique chemical configuration of the nature type 2 collagen.
So We have done a couple of very interesting publications and research work that has created a big momentum in the scientific community, and I would like to highlight two studies that have pivotal in, in, in this, in the, in the.
In the science community, that is the study from 2013 which has been done on healthy subjects and the study from 2016 which has been done on osteoarthritis subjects.
You see on the right side, right side the publications of both research papers and let's take a few moments on the next slide to review the major outcome and the major results of these two studies.
First one, 2013, healthy subjects study, randomized double blind placebo controlled research, two armed group with the UC2 brand group being supplemented with 40 mg of UC2 per day, and the second group, a placebo group, 55 subjects, 120 days' duration, and the primary endpoint was the improvement.
In the knee function, so the range of motion and secondary end points, the time to onset of knee joint on the step mill, and the time to offset of the knee joint pain after the step mill or after stepping off the step mill.
So time to recover.
And all these these subjects that have been tested have been in accordance to the American College of Rheumatology, so people without arthritis, so there was no ill patient, of course, included in this study, and the average age of subject was 46 years, which is a quite moderate, even at the lower side of age population.
Meaning that this also gave us quite an inroad into sports nutrition and into the active consumer field.
So what you see here then is the result of this of this healthy subjects study, and you see the green bars versus the gray bars, which the gray bar is the placebo group and the green bar is the UC2 group, and what is displayed here is that after 90 days, the effect, the increase in average knee extension was significantly enhanced over.
Over baseline and at day 120, it was significantly increased over baseline and over placebo.
So it really is that UC 2 and type 2 collagen is alleviating joint discomfort in again healthy subjects.
It's very important to highlight as typically joint care or joint health studies are conducted with an ill population or people suffering from osteoarthritis or even being on the rescue medication, which certainly here is not the case.
So quite an interesting study in a healthy population.
The 2016 study indeed then is an osteoarthritis study with people suffering in a moderate or severe form of osteoarthritis, again, a randomized double blind placebo controlled study, golden standard, a three arm test designed here with a placebo group, and then it becomes quite impressive as the second group here is the glucosamine chondrotine group that was supplemented with 1.5 g of glucosamine and 1.2 g of chondroitin.
Tested versus the UC2 brand group that has been supplemented with 40 mg.
186 subjects and the primary endpoint was the change in total.
WMAC, which is a very known and clinically widely used self-assessment and scoring system for different pain metrics, the Western Ontario McMaster arthritis codex.
The secondary endpoints here are different scales, different pain scales like the visual analog scale and the LFI and different Bomber subscales that have been tested during the visits of 07, 30, 60, 90, 120, 150, and 180 days.
Population, as we discussed, osteoarthritic subjects in a moderate to severe form, and it was a multi-center.
Study where 13 clinics participated in the study, and when you, when you put your attention to the right, you will see the outcome of the study and the development of the total Womex score, which is being reduced over time for all three groups, which is in fact showing that the pain is reduced.
And however, after day 60, you see the UC2 group here, which is already reaching significance versus placebo after 60 days, after 2 months treatment or 2 months supplementation, and you see next to the star another star, a second star at day 180 that explains and shows that UC2 has reached significance versus placebo and versus the glucosamine chondroitin group.
Whereas at no given time point we see significance between the glucosamine group and the placebo group.
So this is quite an interesting outcome and really highlights the safe and effective features of the UC2 annature type 2 collagen.
Last but not least, another study from 2017, quite new, has been published in July, if I'm not mistaken, July 2017 study done by Bargy in the context of a large pharmaceutical company that is using UC2 in one of the joint care products, and they did a RD study, so pre-clinical work, as they wanted to have a few more objective parameters and assessments that, however, also have the consequence that That it needs to be tested on animals and the UC2 that was used in one of the test groups and Lewis rats that have been supplemented over a certain period of time and there was a group of 10 rats allocated in 4 subgroups a naive control group, which is a placebo group, and a sham control group, which is a group that has Been operated, not really operated, but having a kind of a placebo surgery that means that the joint was just opened, but no harm was done.
There was just a scratching on the surface on the skin, but no meniscus damage was done, so this group was totally intact and fit, whereas the PMMT group is a group of rats that have Been under undergone or that undergone partial medial meniscus tear, meaning that the medial meniscus was has received a transaction.
Which means that it is a kind of a surgery of an injury which is triggering osteoarthritis-like symptoms.
That's a very common methodology in pharmaceuticals or for pharmaceuticals to investigate drugs in joint care.
So indeed these rats have to suffer at the knee.
And being injured, which then is, is, resulting in a dislocation of the knee joint and is triggering inflammation and osteoarthritis.
So one group, the third group indeed, has received the surgery, that's the PMMT group, and they got a placebo product.
And the fourth group then is the group that has also been, received the surgery and was supplemented with the UC2, the UC2 brand.
And as a consequence, then there was different tests that have been applied like the weight bearing capacity, radiography, and histologic sections of the knee joint in order to assess the effect of the supplementation versus the placebo group and the other ones.
So the results are displayed here, you see on the first left, left side you see the four groups, and what we tested here has been.
The force distribution on ground force plates of the different, groups, and the rear right leg.
This is the leg which has received surgery, which has been operated, and you see that.
After a few days, especially the PMMT group that has not been supplemented with UC2 is really very much reducing the weight on the injured knee, and it is very obvious that when your knee is being hurt, that you shift your balance to the healthy, healthy joint to the healthy knee.
That's why the force here on the ground force plate is reduced and is recording less.
Weight on the injured knee of the PMMT group and this is reaching statistical significance after 55 days, meaning the PMMT group is statistically putting less strain and mechanical stress on the knee versus the other groups and also including versus the UC2 group.
You really see the UC2 group here being very much in the area of the placebo group and the sham group.
So very interesting results this clearly showing that UC2 is improving the mechanical function of the injured knee.
On the right side you see in the first quadrant on the top on the blue ones, you see radiographic measures, pictures, and you might know that when one suffers from osteoarthritis, there is the chance that there is the building of osteophytes, so little bone spurs in the outer rim of the knee joint.
And you see this in this where these little white arrows are highlighting the existence of these osteophytes, of these bone spurs that appear that appear with the PMMT group, not with the naive group, not with the sham group, but of course with the group that has been injured, and this osteophyte formation has been reduced or mitigated within the group that has been supplemented with UC2, that's in the lower right quadrant.
Last but not least, the four pictures on the bottom right, they show the the cartilage deterioration, and you might see the dotted line and the solid line at the lower end there again, the UC2 group has been able to, or the UC2 has been able to prevent the joint cartilage deterioration.
So again, very, very interesting results that have been published in the in the ORC paper Osteoarthritis and Cartilage, a very renowned research paper of the Osteoarthritis Research Society International, that is also an organization that is responsible for giving guidelines to the osteoarthritis treatment and community in the US.
So, What I would like to bring to your attention here is the mode of action, the proposed mechanism of action for UC 2.
And the principle of oral tolerance.
And one can say that the daily activities, the daily exercise, the 24/7 stress and strain on, on the knee joint, which is a normal, normal stress, of course, in a way, can lead to joint wear and inflammation.
So that molecules and enzymes are up regulated in the joint area in the synovial fluid and phototochondrocytes that these molecules, these proteins and cytokines, then remove the damage that has been created, the debris that has been created over.
By the activities or by the daily stress, and then the chondrocys switch into a kind of repair mode where they rebuild cartilage matrix and exactly that's where the point where UC 2 plays a role.
It is like an igniter like a key of an engine that is starting the machine and that is triggering and accelerating the rebuild of cartilage matrix.
I think we have on the next slide a little video that displays and shows you a bit more how this works on a molecular level, and bear with me here.
UC2 under-natured type 2 collagen is a safe and uniquely effective dietary ingredient for joint health.
Three human clinical studies support the efficacy and safety of UC2 under-natured type 2 collagen.
When taken orally, it is hypothesized that intact UC2 molecules reach a specialized area of the small intestine called the payer's patch.
Once UC2 unnatured type 2 collagen makes contact with the payer's patch, it is proposed to work with the immune system.
To help promote flexibility and mobility.
UC2 un-natured type 2 collagen interacts with a special class of cell called a T-regulator, which goes on to produce several regulatory molecules that are transported by the body to the overstressed knee joint.
Upon arrival at the knee joint, resident chondrocytes, whose main job it is to maintain a healthy knee joint, are induced by these regulatory molecules called cytokines.
IL-10 and TGF beta are the two cytokines produced by the T regulators that play a key role.
In this rebuilding process to begin producing more type 2 collagen and other constituents that make up the structural matrix of the knee joint.
In this way, it is believed that ingesting UC2 under-natured type 2 collagen results in a more rapid restoration of the healthy knee joint.
So, In principle, the video displayed explained and showed that , That this is quite a unique mode of action for the type 2 collagen and again on this slide here it's shown how it works.
So if one can summarize that the UC2 is taken orally and is then moving through the gastric fluid towards the intestine and here.
It is absorbed, not absorbed with a B, but throb with a D, so it is absorbed in the gut in the pale patch, which is a collection of immune cells located at the gut, the gut associated lymphoid tissue, and here by Yeah, by a series of molecular action, T regulatory cells are, are rising as a consequence of a biochemical complex, and these T regulatory cells are then distributed by the lymphoid tissue towards the areas of inflammation like the joint, joint of the knee, and here they get activated and they release, interleukin 10, for example, and TGF beta, which then, helping the contrasites to get into repair mode and build new cartilage matrix.
So UC2 really goes to the source of the issue.
It is not about applying building blocks.
It's not about getting UC2 in the bloodstream and then bringing it to the knee joint.
That's really not the mode of action here.
This is really a different cup of tea and a very different mechanism as I introduced at the very early beginning of my slides.
So, great opportunity to, to launch new products with UC2, great opportunity to, to come up with fresh, innovative products in the mobility segment and we introduced here a product that has been developed and is, is ready for the market.
And this is a pure EC2 product that has been enriched with vitamin C, vitamin D3, manganese, and copper because these ingredients, these vitamins and minerals that have EFSA approved health claims on joint health like the contribution to the maintenance of normal bones and the normal formation of connective tissue and collagen.
And we see here a a animation, a mockup of a packaging, how it could like, how it, how it could look like, excuse me, where you see the UC2 brand highlighting and being really put into the forefront showcasing the difference here and of the product of this innovation, but at the same time being very, very.
Very compliant in the way we come to the point of doing health claims here on the product, and we also feature the small daily dose, just a one a day product versus the bigger typical supplements that are used in joint care, which is very important as 75% of consumers consider easy to swallow as a very important feature.
In for buying dietary supplements, and this capsule, due to the small dose of the UC 2 and the 40 mg is a very small size.
3 V caps that is really very small if you know the nomenclature of the size here.
A size 3 capsule is typically much half the size than I would say for a typical capsule form.
So we have really developed a complete range of ready to market products.
So UC 2 is here embedded and moving with the times, and we have combined antioxidants as we just showed with UC2.
We also have opportunities and creative products that make use of the botanical beauties that are so.
High in demand actually like the curcumin or Busvalia, but also the anti-inflammatory benefits of the omega 3 fatty acids or the vitamin D3 as as vitamin K2.
So we have a fully fledged offer from antioxidants over anti-inflammatory support towards bone health in very different dosage forms that you can see on the right side here.
So let's take a moment here to look into the anti-inflammatory strategies and products that are used in joint care.
So here's a selection of natural solutions of human ayurvedic botanical approaches to joint inflammation like high, very high bioavailable, bioavailable liquid curcumin.
That you see here, it says 185 times increased bioavailability due to its very different solubilized myllar structure here in a liquid form in the lee caps, very unique, and the second product here is a 56 times bioavailability increased bos failure again in a vegetarian-based liquid form here.
And on the last, the last one we show here on the left side is a high, high dose EPA product, EPA DHA, whereas the focus here is on the EPA from the anti-inflammatory side.
So these products then really come from different angles, having different mechanisms of actions to inhibit different.
Oxidative or inflammatory drivers and messengers, and by this means have anti-inflammatory properties.
All this can be combined or can be a line extended with a UC2 product that again has a different mechanism of action and is triggering the natural rebuild of cartilage in the joint.
So a very holistic perspective towards mobility and joint joint care coming from different chemical pathways and different chemical.
Nutrients towards a, a approach and a.
More comprehensive, joint care.
What we also might consider is combining innovative dosage forms with this approach.
So what you see here is a capsule in capsule technology that is called dual cap, very refreshing kind of dosage form, very cool looking, very unique, but also very strong technical claims and technical benefits like here the opportunity to combine.
Highly bioavailable liquid curcumin, which is also branded as Novasol, a solubilized form of curcumin that is embedded in the liquid form in the liquid capsule, and inside of this liquid form there's a small size 3 UC2 capsule.
So then we don't interact with the bioavailability enhanced system of the liquid curcumin and at the same time we protect the UC2, so we have two compartments here in a dual cap but still just one capsule to swallow shown on the right here, the dual cap curcumin active once a day in.
In a more marketing context where we showcase the small size UC2 capsule and at the same time make a kind of a marketing illustration here that you know that the very liquid clinically studied bioavailability of the curcumin is replacing a high number of typical capsules or tablets that usually have to be used in order to reach.
A good dose, a beneficial dose of curcumin due to the fact that curcumin has a very, very low bi bioavailability in its native form.
So, there's also a big buzz around vitamin K2.
And it is one of the vitamins that has received a great deal of attention from the scientific community, but also from the consumers.
So we have here a product that is a liquid product, a lee caps, that is using a lipophilic base in which the fat soluble vitamin K2 and vitamin D3 are embedded.
And solubilized, and this is enriched with vitamin C and of course EC2, so a product that triggers the chondrocytes to rebuild cartilage by the use of UC2 and vitamin K2, that is ensuring the activation of the bone building protein osteocalcin, that is then also helping to remove the calcium out of the bloodstream into the bones where it is needed.
To reduce the risk of osteoporosis.
So great joint care, bone health, combination here.
Enriched with vitamin C and vitamin D3 for additional joint and bone and cartilage claims.
So this really brings me to The end and here I would like to conclude at least from my side by giving you a few takeaways and we have seen also by the introduction that the changing.
The consumer landscape is changing and it requires a different approach to to joint health or it's it's time or time is ripe to to leave the one size fits all model behind and come to different options for for different audience.
We have seen that the UC2 brand is strongly backed by science and.
Has interesting and we only have seen a few of the publications.
There are of course more to be found, and we have seen it has a unique mode of action and a very small required dose per day of just 40 mg that makes it very attractive to replace bulkier, less efficacious ingredients for finally a smaller serving size and ultimately for better customer compliance and experience.
We've also seen that new innovations in dosage form techniques and technologies like vegetarian recaps plus or the dual cap capsule and capsule technology, as as a liquid dose recaps form, are innovative ways to combine ingredients in a synergistic way and enhance the overall compliance and convenience of a single dose once a day supplement.
So at this point I would like to thank you very much for now for the attention, and I think I'll pause here for a moment to see if I still have any questions or there's still any questions around, and I will hand back to you, Robin.
Thank you.
Thank you very much, Dominic, for this very interesting presentation on this very topical field of, of joint health.
So in a moment we're going to go to a few questions.
I think there's lots of things to discuss here.
So if you have any questions, just please fill them into the chat box.
Just another note that there are a couple of corresponding handouts to this presentation.
So if you go to the bottom, the 3rd icon on the bottom of your screen, which looks like a lot like a handout, you can click on that and that will allow, allow you access to these 22 detailed handouts on some of these ingredients.
So, we're going to go now to, to a few questions, and, maybe Dominic, I'll begin with a couple of things that I, I was going to ask myself and, which type of markets do you see the, the biggest potential growth opportunities for collagen and how are you going to be looking to address them from a, from a company standpoint?
Yeah, Robin, thank you, great question.
I think it is, it is safe, safe to say that, first of all, the aging population continues to grow, and, and together there, there's a generation that is also more concerned about.
Healthy aging and, and I think there's a global increase in demand for, for joint and bone health simply due to the demographic change, but also to the fact that the, the everyday chore is, is, is, learning so much more about nutrition and about the preventive.
Benefits of proper nutrition and certain nutrients.
So there's an overall a stronger interest to learn more about actives and to learn more about the benefits of certain nutrients, and the consumers are very willing to learn about them.
And as we see an overall shift to performance and being active and being healthy and taking a preventive lifestyle approach.
We're pretty sure that joint health will not just be of great benefit for the elderly, but likewise for the younger generation and the millennials that we have introduced before.
So from, from, from treatment and and illness to wellness and prevention up to performance and elite athletes, it is appealing to all of them, I think.
Yeah, indeed it has applications across the board to really target many different generations.
I think there's, there's, there's huge opportunities there.
But what, what, what, what type of challenges might a, might a product developer face when working with UC2 and how, how, how can they be overcome?
I rather see advantages than than rather challenges for for UC2, and I think I showed it in one of the last slides that the very small dose per day, the 40 mg, which gives the product a great deal of of formulation flexibility.
Meaning you can easily embed this small dose in more complex formulations and still have a product that is easy to swallow in terms when we speak about traditional forms like tablets, capsules or soft gelatin capsules.
So this is very favorable for the dosage form and the compliance and convenience of the consumers.
So here truly is an advantage.
In terms of, when you think about more, I wanna call them taste driven formats like like gums or bars and and and balls and bites and whatever whatever you you may call them.
We don't have yet so much experience.
We are looking into beverages.
We're looking into gummies, but as we are a science, science-based company, of course we want to make sure that the shelf life is, is there and the stability of our shelf life is there.
So this is then, of course, a development and if there's a customer interested in more of these, in these different forms, then, yeah, you have maybe my number or my email and I'm happy to assist you.
Yeah, because that, that was one of the questions that was coming up from Matt.
It was really about the, the format of U2 is, is within a capsule form.
Are, are there really opportunities to include it as a food ingredient?
And I guess it's an area that you're, you're really looking towards increasingly.
Yeah, I think if I may add on this, there's 1.1 remark, as you've seen the studies we did, is on a daily supplementation.
So when you think about a beverage or a bar, which is more like a convenience functional food, then it might make sense to embed UC 2 here for joint health.
And as long as you make sure that the consumer takes it every day, drinks the beverage, and takes the bar every day, because as you've seen in the study, you have a significance of.
Treatment or let's call it better supplementation after 60 days.
So this should be considered when when you design the final product.
But have you done tests then to see about the survival through the digestive process?
We have, we're working on that.
We're looking into different forms, like I said, it's, it's still for a moment like more proprietary information.
But we did this, and what we have done, what we have proven in studies already, is that the UC2 is stable in gastric juice for more than 90 minutes, and these very important epitopes, the molecular regions I explained before, that are so important for the efficacy of UC2, we have proven in a proprietary laser test in an analytical assay, which is quite complex, by the way, we have proven that.
Our UC2 is surviving gastric acid and gastric juice, so this is not a problem, but I would say we have to make sure that a certain humidity is, is, is, is.
Is excluded from the product in the long term.
So there are a few points that we might have to watch this and to take care of.
But overall it is safe to say that the product is very versatile and it's it's it's widely used in powder forms for the moment.
And again we're looking into also some more fun formats, but if I may add here one point is, is that there's, if, if I speak to customers, right, you sometimes have customers that say I would like to have more like these, these taste driven formats like 50, maybe 30% of the more younger generation and, and customers we have say this, but still 70% tell me.
We would like to have a product like this in a more medical form because the efficacy is great and the science is great.
It has a very pharmaceutical approach or appeal in a way to joint care, to osteoarthritis management, so we have a big chunk of business and customers who really want to have a more like a medical perceived container like the traditional tablet or capsule types.
But I think that's kind of an interesting point is because the question here from Tanya is how, how, how long should the intake last in order for the first results to be seen and can the product really fully rejuvenate human cartilages and joints.
So the studies, we only claim what the studies tell us.
So the studies show that the healthy adult study shows a significance after 90 days, and the bigger study we showcased here, the glucosamine treatment, the study of UC and glucosamine treatment showed significant results after 60 days.
So 2 month supplementation should be the minimum according to the studies.
And that's only what I can claim here to be serious.
However, we have anecdotal information from from friends and families and customers that take the product and that even report back a big change or a transformational change more or less overnight.
But again, this is, it wouldn't be very serious to claim this year strongly, but it is information that is encouraging and That is, is, yeah, it's, it's, it's, it's good to hear.
It's also expanding then out of the knee joint into like arthritis in the fingers that we have customers reporting back that it has improved this enormously in in in in in the health of the hand in the fingers and not just the knee joints.
So but again we can only claim and and talk about what we have clinically substantiated.
That's, that's interesting.
That's, that's, that's very interesting indeed because it, it has multiple benefits.
It's not, not just for knees.
Another, another question that was here was, was, does, does UC2 also work for, for pets?
Have there been any kind of a test done in, in animals with this, with this product?
Yeah, that's that's a great question, and you may not be surprised that our animal friends like the dogs and the cats, they suffer kind of same of noncommunicable diseases as humans do, like obesity and arthritis is a big thing.
And a big issue in in companion animal health, and we have 6 published studies on UC2 in in in in dog research and horses.
I think there have been like, if I'm not mistaken, 5 studies for dogs and 1 for horses and the latest one, which is then the study on rats, the buggy study that I have presented here also during this webinar.
So yes, there is, there is, humans are not the only ones who suffer from arthritis, and indeed there is a need also for, for, for pets, and there is already a few companies out there that sell the product in the veterinary channel, very successful, and they are great studies, like I said, the Gupta study, for example, that has proven and tested UC2 again versus glucosamine chondroine.
And also making use of ground force plates to see how the animal is distributing weight on the knee joints, and they have seen that UC2 indeed is really increasing the performance of the animals and also the pain scale is improving for the UC2 group with significance.
That's very interesting indeed, good to hear.
Fine, I guess we just have time for, for one last question.
Just want, want, want to ask you was, , what else?
There's obviously a lot going on at the moment at, at Loans of Capsule.
What, what, what else is kind of in the development pipeline when it comes to this field of joint health, etc.
And, what, what can we expect to see moving forward?
You're obviously looking at different application areas and, and moving more towards functional foods, etc.
What, what, maybe, maybe you can briefly explain what, what we can expect to see going forward.
Yeah, I think The view is that that here two market leaders come together like a cups of shell from the dosage from technologies and the innovative innovative part of delivery tech techniques and Alonsa from the science ingredients perspective and bringing these two to.
Two elements together is creating a real powerhouse in nutrition and supplementation and also functional foods, and the UC 2 is just one very shiny but one example of how we bring together the expertise from two different angles and building turnkey solutions alongside mega trends and for UC 2 we really want to embed it into a mobility program.
So we think that it is also important to adhere to a certain dietary pattern than just rely on one single magic ingredient maybe.
So we want to really take a multimodal approach to osteoarthritis management.
That's why we have showcased here the opportunities that come along with turmeric, anti-inflammatory benefits of curcumin.
The bosphic acids, the EPA, DHA omega 3s, together with UC2s are really from different battlefronts, we look into into joint care.
So this whole mobility universe that opens up here is, is interesting for us, and that's something we want to try forward and that's something that we want to really encourage people to look for the UC2 brand but also for.
For, yeah, the different opportunities that we bring to our customer base and to maybe close here on on this train of thought is is also that we really have here the commitment to.
To drive UC as a brand and joint health and we're really also working already with key opinion leaders in different markets and are very excited and encouraged by the positive feedback we get from the audience, is it a medical audience or the end consumers, so I think rest assured there's more to come.
Very interesting indeed and lots of lots of synergy opportunities there between, between various nutraceuticals.
Thank you very much.
That's about all we have time for today.
So thank, thank my thanks to Dominic, the return of Lanza Capsule.
So of course if you have any further questions or inquiries regarding our on our services and apologies if we didn't get around to answering your questions today but but Alonzo we'll get back to you regarding them because I think there were there were so many questions that came in but otherwise you can also share your feedback in a short survey which we're going to feature after the webinar.
And for any further questions regarding our webinar and services, feel, of course, feel free to email me at Robin@cnsmedia.com or visit our website at nutritioninsight.com in order to keep up to date with the latest developments within the nutraceutical space.
But for now, thanks again for your attention today and have a have a wonderful rest of the day.
